Search
Janux Therapeutics Inc
JANXAdd to Watchlist
15.540USD
+0.880+6.00%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
945.85MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Janux Therapeutics Inc is 8.20, ranking 155 out of 387 in the Biotechnology & Medical Research industry. The average price target is 53.50, with a high of 200.00 and a low of 32.00.
Analyst Rating
Based on
20
analysts
Buy
Current Rating
37.529
Target Price
+144.89%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Janux Therapeutics Inc
JANX
20
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Janux Therapeutics Inc's expected revenue for the next quarter?
Janux Therapeutics Inc's expected revenue is 12.35M.
What is Janux Therapeutics Inc's price target?
Analysts forecast that Janux Therapeutics Inc's price target is USD 53.50, with the highest forecast at USD 200.00 and the lowest forecast at USD 32.00.
How have Janux Therapeutics IncJANX's recent earnings per share performed?
The market expectation was USD -0.39, while Janux Therapeutics IncJANX's earnings per share (EPS) for the previous quarter was USD -0.51. EPS for the next quarter is expected at USD -0.42.
What is the analyst rating for Janux Therapeutics Inc?
Based on the ratings of Janux Therapeutics Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.